学术报告

您所在的位置:首页 >> 学术科研 >> 学术报告 >> 正文

药学前沿大讲堂第366讲

点击数:154 作者:药学院 编辑:药学院 来源:药学院 提醒时间:2018-04-19

    : Overcoming cancer cell drug resistance by targeting P-glycoprotein in the lysosome: The development of novel di-2-pyridylketone thiosemicarbazones

报告人: Des R. Richardson 教授,悉尼大学

主持人:毕惠嫦 教授,中山大学药学院

    : 2018419日(星期四)15:00-16:00

    : 中山大学东校园药学院112会议室


报告人简介:

Professor Des Richardson holds the Chair of Cancer Cell Biology at the University of Sydney, Australia, and is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow.  

He has published > 406 articles, reviews, patents, chapters etc., over his career with >93% as first, senior or corresponding author (H-index: 80; >25,060 citations over entire career; with >14,523 citations over the past 5 years and H-index: 57 over past 5 years).  

He is Executive Editor of BBA-General Subjects and has served on the Editorial Boards of >40 international journals, including J. Biol. Chem., Antioxidants Redox Signaling, Biochem. J., BBA-Mol Cell Res, Mol. Pharmacol., Pharmacol. Res., etc. 

As a major translational research achievement, he has developed the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein mediated drug resistance. This has led to commercialisation of DpC and the development of the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC has entered multi-centre Phase I clinical trials for the treatment of advanced and resistant cancer. These anti-cancer drugs target the lysosome via the P-glycoprotein transporter.

 

欢迎广大师生踊跃参与!


分享本文: